Informed Prostate Cancer Patient Support

Personalized dosing improves outcomes for men with metastatic castration-resistant prostate cancer news-medical.net Reviewed by Megan Craig, M.Sc.Jun 26 2023 By monitoring early-response biomarkers in men undergoing 177 Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes. In a study presented at the Society of Nuclear Medicine and Molecular Imaging 2023 Annual Meeting, early stratification with 177 Lu-SPECT/CT allowed men responding to treatment to take a "treatment holiday" and allowed those not responding the option to switch to another treatment. Approved by the U.S. Food and Drug Administration in 2022, 177 Lu-PSMA is an effective treatment for metastatic castration-resistant prostate cancer. However, not all men respond equally to treatment, with some respond

Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers | Novartis : Pluvicto is an intravenous radioligand therapy (RLT) combining a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)2,3. After administration into the bloodstream, Pluvicto binds to target cells, including prostate cancer cells that express PSMA, a transmembrane protein2,3. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death3.

“Mind-Blowing” Cancer Discovery – Common Chemotherapy Drugs Don’t Work Like Doctors Thought scitechdaily.com University of Wisconsin-Madison New research challenges the traditional belief about how microtubule poisons, a class of cancer drugs, work. Instead of stopping cancer cells from dividing, these drugs alter the process, sometimes causing new cancer cells to die. The findings provide insights into why certain drug discovery attempts were unproductive and suggest a need to focus on disrupting the cell division process differently. The research uncovers the likely reason why certain chemotherapies are effective for many patients. Importantly, they also shed light on why endeavors to discover new chemotherapy drugs based solely on stopping cellular division have been so disappointing. Recent research from the University of Wisconsin–Madison indicates

Multinational Study Suggests High Variability with Quality of Prostate MRI diagnosticimaging.com Jeff Hall In a study of 355 multiparametric prostate MRI exams from a total of 71 scanners from 41 facilities in 18 countries, researchers found that only 23 scanners achieved a PI-QUAL score of 5 for optimal image quality. Emerging research from a multinational study involving over 40 facilities reveals a significant degree of variability with the quality of imaging for prostate multiparametric magnetic resonance imaging (mpMRI) exams. For the multicenter study, recently published in Radiology , researchers utilized the PI-QUAL scoring system to assess 355 mpMRI exams performed at 41 facilities in 18 countries from September 2021 to August 2022. Out of a total of 71 MRI scanners, the researchers found that only 23 scanners (32 percent) achieved a PI-QUAL score

Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction | medRxiv medrxiv.org Thomas J Hoffmann , Rebecca E Graff , Ravi K Madduri , Alex A Rodriguez , Clint L Cario , Karen Feng , Yu Jiang , Anqi Wang , Robert J Klein , Brandon L Pierce , Scott Eggener , Lin Tong , William Blot , Jirong Long , Timothy Rebbeck , Joseph Lachance , Caroline Andrews , Akindele O Adebiyi , Ben Adusei , Oseremen I Aisuodionoe-Shadrach , Pedro W Fernandez , Mohamed Jalloh , Rohini Janivara , Wenlong C Chen , James E Mensah , Ilir Agalliu , Sonja I Berndt , John P Shelley , Kerry Schaffer , Mitchell J Machiela , Neal D Freedman , Wen-Yi Huang , Shengchao A Li , Phyllis J Goodman , Cathee Till , Ian Thompson , Hans Lilja , Stephen K Van Den Eeden , Stephen J Chanock , Jonathan D Mosley , David V Conti , Christopher A Haiman , A

Imaging and Biomarker Testing Considerations in Prostate Cancer A 66-Year-Old-Man with Prostate Cancer and a 78-Year-Old Man with Metastatic Prostate Cancer : Episode 2 September 22, 2023 Paul M. Yonover, MD, FACS Opinion Video An expert on prostate cancer discusses the clinical application of imaging and biomarker testing for patients with prostate cancer. Current Time  0:28 / Duration  4:56   EP: 1. Patient Profile 1: A 66-Year-Old-Man with Prostate Cancer Now Viewing EP: 2. Imaging and Biomarker Testing Considerations in Prostate Cancer EP: 3. Treatment Options for Patients With Prostate Cancer EP: 4. High-Risk Prostate Cancer: Treatments Following Radical Prostatectomy EP: 5. Patient Profile 2: A 78-Year-Old Man with Metastatic Prostate Cancer EP: 6. Treatment Considerations for Patients With High-Risk, High-Burden Prostate Cancer EP: 7. Unmet Needs Surrounding the Treatment of Prostate Cancer Case #1: A 66-Year-Old-Man with Prostate Cancer Initial Presentation (June 2022) A

Docetaxel radiosensitizes castration-resistant prostate cancer by downregulating CAV-1: International Journal of Radiation Biology: Vol 0, No 0 tandfonline.com Docetaxel radiosensitizes castration-resistant prostate cancer by downregulating CAV-1 Nrusingh C. Biswal 6–7 minutes Abstract Purpose: Docetaxel (DXL), a noted radiosensitizer, is one of the few chemotherapy drugs approved for castration-resistant prostate cancer (CRPC), though only a fraction of CRPCs respond to it. CAV-1, a critical regulator of radioresistance, has been known to modulate DXL and radiation effects. Combining DXL with radiotherapy may create a synergistic anticancer effect through C

Microultrasound in the detection of the index lesion in prostate cancer - Pedraza - The Prostate - Wiley Online Library onlinelibrary.wiley.com Adriana M. Pedraza MD ORIGINAL ARTICLE Abstract Introduction and Objective The natural progression of prostate cancer is primarily driven by an index lesion (IL) . Studies have shown that different metastases within the same patient arise from a single precursor cell. Therefore, our aim is to assess the effectiveness of transrectal microultrasound (MUS) in comparison to multiparametric magnetic resonance imaging (mpMRI) for detecting the IL in prostate cancer. We used quarter-mount pathological results as the reference standard for this evaluation. Materials an

How this device uses sound waves to destroy tumors | Popular Science Histotripsy is a non-invasive cancer treatment that uses ultrasound to break up tumors in the body. It uses controlled sound waves to create micro-bubbles to destroy the targeted diseased tissue, eliminating the use of radiation, chemotherapy and surgical incisions. It was developed over 20 years ago by Michigan Engineering researchers in collaboration with clinicians @MichiganMedicine and the U-M Rogel Cancer Center, and later brought to clinical use by Minneapolis based company HistoSonics. https://news.engin.umich.edu/2023/10/... After successful clinical trials in Europe and the United States, where the  HistoSonics Edison Platform was used to treat patients with metastatic liver tumors, the Food and Drug Administration has approved the use of histotripsy in hospitals worldwide. With the FDA approval, Histosonics can now sell the Edison Platform to hospitals, giving liver cancer patients a non-invasive treatme

Real-world evidence of triplet therapy in metastatic hormone-sensitive prostate cancer - an Austrian multicenter study | medRxiv medrxiv.org Real-world evidence of triplet therapy in metastatic hormone-sensitive prostate cancer - an Austrian multicenter study Mona Kafka 5–6 minutes   Follow this preprint , Giulia Giannini , Nastasiia Artamonova , Hannes Neuwirt , Heidemarie Ofner , Gero Kramer , Thomas Bauernhofer , Ferdinand Luger , Thomas Höfner , Wolfgang Loidl , Hubert Griessner , Lukas Lusuardi , Antonia Bergmaier , Andreas Berger , Thomas Winder , Sarah Weiss , Severin Bauinger , Steffen Krause , Martin Drerup , Elmar Heinrich , Magdalena Schneider , Stephan Madersbacher , Sonia Vallet , Franz Stoiber , Sarah Laimer , Stephan Hruby , Gert Schachtner , Udo Nagele , Sebastian Lenart , Anton Ponhol

Advancing cancer biomarker detection | Drug Discovery News drugdiscoverynews.com Advancing cancer biomarker detection ~2 minutes Webinar Molecular biomarkers offer a wealth of information that facilitates accurate cancer diagnosis and guides treatment strategies. Recent technological advances have unlocked the identification of diverse biomarker types, including extracellular vesicles (EVs), proteins, carbohydrates, DNA, and RNA. In this seminar, Anton Iliuk, Brian Haab, Yong Zeng, and Brian Cunningham will discuss innovative approaches to detect biomarkers for cancer diagnosis, prognosis, and treatment assessment.  Topics to be covered Developing non-invasive cancer diagnostics using EV protein biomarkers  Probing glycan biomarkers for pancreatic cancer diagnosis and prognosis Engineering biosensors to profile EV biomarkers for cancer liquid biopsy Designing